CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
NCT02316171
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
BIOLOGICAL:
CVA21
DRUG:
Mitomycin C
Sponsor
Viralytics